Vemurafenib
Cat. No.：YN350099
| 产品名称: | Vemurafenib |
| CAS No.: | 918504-65-1 |
| Chemical Name: | N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide |
| Synonyms: | 维罗非尼; PLX4032; RG7204; RO5185426 |
| 分子量: | 489.92 |
| 分子式: | C₂₃H₁₈ClF₂N₃O₃S |
| SMILES: | FC1=CC=C(C(F)=C1C(C2=CNC3=NC=C(C=C32)C4=CC=C(C=C4)Cl)=O)NS(CCC)(=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Vemurafenib (PLX4032; RG7204; RO5185426) 是首创的，有效的B-RAF选择性抑制剂，能够抑制 RAFV600E和 c-RAF-1 的活性，IC50分别为 31 nM 和 48 nM。Vemurafenib 可以诱导细胞自噬 (autophagy)。 |
| IC50和靶点: | [{name:"B-RafV600E:31 nM (IC50)"},{name: "c-Raf-1:48 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Khazak, V., Astsaturov, I., Serebriiskii, I.G., et al.Selective Raf inhibition in cancer therapyExpert Opin. Ther. Targets11(12),1587-1609(2007)
Flaherty, K.T., Puzanov, I., Kim, K.B., et al.Inhibition of mutated, activated BRAF in metastatic melanomaN. Engl. J. Med.363(9),809-819(2010)
Bollag, G., Hirth, P., Tsai, J., et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature467(7315),596-599(2010)
Coffee, E.M., Faber, A.C., Roper, J., et al.Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancerClin. Cancer Res.19(10),2688-2698(2013)
Huang, T., Karsy, M., Zhuge, J., et al.B-Raf and the inhibitors: From bench to bedsideJ. Hematol. Oncol.6,1-9(2013)
